Top Neuroendocrine Tumors Treatment Companies

Global Neuroendocrine Tumors Treatment Market size was valued at USD 2.48 Billion in 2024 and is poised to grow from USD 2.62 Billion in 2025 to USD 4.11 Billion by 2033, growing at a CAGR of 5.8% during the forecast period (2026–2033).

Due to the presence of a sizable number of participants, the market is quite competitive. To increase their consumer base, the majority of businesses are engaging in strategic alliances like mergers and acquisitions. To draw in more customers, players are diversifying their product offerings. 'Novartis AG (Switzerland) ', 'Bristol Myers Squibb Company (US) ', 'Pfizer Inc. (US) ', 'Boehringer Ingelheim International GmbH (Germany) ', 'Hutchison MediPharma Limited (China) ', 'AVEO Pharmaceuticals, Inc. (US) ', 'Ipsen Pharma (France) ', 'Eli Lilly and Company (US) ', 'Exelixis, Inc. (US) ', 'Jubilant Pharmova Limited (India) ', 'F. Hoffmann-La Roche Ltd (Switzerland) ', 'Viatris Inc. (US) ', 'Thermo Fisher Scientific Inc. (US) ', 'Regeneron Pharmaceuticals, Inc. (US) ', 'Sun Pharmaceutical Industries Ltd. (India) ', 'Teva Pharmaceutical Industries Ltd. (Israel) ', 'Lupin (India) ', 'Exact Sciences Corporation (US) ', 'Advanced Accelerator Applications (France) ', 'BioSynthema Inc. (US)'

The incidence and prevalence of neuroendocrine tumors (NET) are steadily rising worldwide, according to the data from the American Society of Clinical Oncology (ASCO). Because of this, the adoption rate of the medications for the treatment of this rare condition is aided by the rising prevalence of neuroendocrine tumors.

The neuroendocrine tumor treatment market is anticipated to be dominated by somatostatin analogs: As they limit tumor growth, symptoms, and biomarkers, somatostatin analogs (SSAs) are discovered to be the medications most frequently utilized to treat the neuroendocrine tumor. Due to the safe treatment methods provided by SSAs, they account for the greatest revenue share. Patients who are sensitive to radiotherapy and surgery are found to typically be treated with SSAs. Since many SSAs are presently in the clinical trial stage and awaiting approval, the market is anticipated to have rapid growth throughout the forecast period.

Based on region, North America is predicted to experience considerable growth in the neuroendocrine tumor treatment market, due to the increasing acceptance of novel neuroendocrine tumor treatments in the region. For instance, Ipsen's Somatuline Depot (lanreotide) Injection 120 mg was approved by the U.S. Food and Drug Administration (FDA) and it is intended for the treatment of adults with advanced or metastatic, moderately-differentiated, locally advanced, or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs).